Non-Hodgkin's lymphoma vaccine - CellGenix
Alternative Names: IdioVaxLatest Information Update: 03 Jun 2015
At a glance
- Originator CellGenix Technologie Transfer
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma
Most Recent Events
- 05 Dec 2006 Phase-II clinical trials in Lymphoma in Germany (unspecified route)
- 18 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Haematology (ASH-2003) have been added to the adverse events and Cancer immunogenicity section
- 02 Oct 2001 Phase-I clinical trials for Lymphoma in Germany (Unknown route)